keyword
MENU ▼
Read by QxMD icon Read
search

Vedolizumab

keyword
https://www.readbyqxmd.com/read/28981886/perioperative-use-of-vedolizumab-is-not-associated-with-postoperative-infectious-complications-in-patients-with-ulcerative-colitis-undergoing-colectomy
#1
Marc Ferrante, Anthony de Buck van Overstraeten, Nikkie Schils, Annick Moens, Gert Van Assche, Albert Wolthuis, Séverine Vermeire, André D'Hoore
Background and Aims: Preoperative use of vedolizumab has been associated with increased short-term postoperative infectious complications. We assessed this risk in a single-centre cohort of patients with ulcerative colitis undergoing colectomy. Methods: Chart review was performed for all colectomies between 2006 and 2016. Short-term postoperative [non]infectious complications were evaluated within 30 days after colectomy. The comprehensive complication index was calculated based on all reported events...
July 12, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28978958/vedolizumab-in-patients-with-common-variable-immune-deficiency-and-gut-inflammation
#2
Brigid S Boland, Marc A Riedl, Mark A Valasek, Sheila E Crowe, William J Sandborn
No abstract text is available yet for this article.
October 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28978957/long-term-combination-therapy-with-anti-tnf-plus-vedolizumab-induces-and-maintains-remission-in-therapy-refractory-ulcerative-colitis
#3
Sarah Fischer, Timo Rath, Carol-Immanuel Geppert, Bernhard Manger, Georg Schett, Markus F Neurath, Raja Atreya
No abstract text is available yet for this article.
October 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28974896/access-to-biologicals-in-crohn-s-disease-in-ten-european-countries
#4
Márta Péntek, Peter L Lakatos, Talitha Oorsprong, László Gulácsi, Milena Pavlova, Wim Groot, Fanni Rencz, Valentin Brodszky, Petra Baji, Crohn's Disease Research Group
AIM: To analyze access (availability, affordability and acceptability) to biologicals for Crohn's disease (CD) in ten European countries and to explore the associations between these dimensions, the uptake of biologicals and economic development. METHODS: A questionnaire-based survey combined with desk research was carried out in May 2016. Gastroenterologists from the Czech Republic, France, Germany, Hungary, Latvia, Poland, Romania, Slovakia, Spain and Sweden were invited to participate and provide data on the availability of biologicals/biosimilars, reimbursement criteria, clinical practice and prices, and use of biologicals...
September 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28973005/a-systematic-review-of-cost-effectiveness-studies-comparing-conventional-biological-and-surgical-interventions-for-inflammatory-bowel-disease
#5
Nadia Pillai, Mark Dusheiko, Bernard Burnand, Valérie Pittet
BACKGROUND: Inflammatory bowel disease (IBD) is a chronic disease placing a large health and economic burden on health systems worldwide. The treatment landscape is complex with multiple strategies to induce and maintain remission while avoiding long-term complications. The extent to which rising treatment costs, due to expensive biologic agents, are offset by improved outcomes and fewer hospitalisations and surgeries needs to be evaluated. This systematic review aimed to assess the cost-effectiveness of treatment strategies for IBD...
2017: PloS One
https://www.readbyqxmd.com/read/28961959/the-expanding-therapeutic-armamentarium-for-inflammatory-bowel-disease-how-to-choose-the-right-drug-s-for-our-patients
#6
Pieter Hindryckx, Niels Vande Casteele, Gregor Novak, Reena Khanna, Geert D'Haens, William J Sandborn, Silvio Danese, Vipul Jairath, Brian G Feagan
The therapeutic landscape for inflammatory bowel disease (IBD) is rapidly evolving. Two new biologic drugs, vedolizumab and ustekinumab, have recently entered the marketplace, the first biosimilars have been introduced, and several other agents are at an advanced stage of clinical development. In parallel, therapeutic goals have shifted from symptom control towards mucosal healing and prevention of bowel damage. In the coming years, gastroenterologists will be faced with unprecedented choices when selecting the best treatment for their patients with IBD...
August 25, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28961712/vedolizumab-levels-in-breast-milk-of-nursing-mothers-with-inflammatory-bowel-disease
#7
Adi Lahat, Ariella Bar-Gil Shitrit, Timna Naftali, Yael Milgrom, Rami Elyakim, Eran Goldin, Nina Levhar, Limor Selinger, Tzufit Zuker, Ella Fudim, Orit Picard, Miri Yavzori, Shomron Ben-Horin
Introduction: There are no data on the transfer of vedolizumab in breast milk of nursing mothers. We aimed to assess the presence of vedolizumab in breast milk of nursing inflammatory bowel disease (IBD) patients. Methods: This was a prospective observational study of vedolizumab-treated breast-feeding patients with IBD. Serum and breast milk samples were obtained at pre-defined time-points. The in-house developed ELISA assay for measuring vedolizumab in blood was adapted and validated for measurement of drug in breast milk...
August 31, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28953016/nodular-vasculitis-in-a-patient-with-crohn-s-disease-on-vedolizumab
#8
Delila Pouldar, Ashley Elsensohn, Francesca Ortenzio, Jessica Shiu, Michael McLeod, Sébastien de Feraudy
Erythema induratum (EI), or nodular vasculitis (NV), is a type of panniculitis that is often associated with vasculitis affecting various-sized veins, venules, and arteries in reaction to various causative factors. Historically, EI was highly linked to tuberculosis, but in 1946, Montgomery first proposed the term NV to describe cases of EI not associated with tuberculosis. Only 2 reports of NV associated with inflammatory bowel disease have been reported in the literature. The authors report a 60-year-old woman with Crohn's disease presenting with exacerbation of NV in the setting of vedolizumab therapy...
September 20, 2017: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/28919373/treatment-of-chronic-granulomatous-disease-associated-fistulising-colitis-with-vedolizumab
#9
Nicholas Campbell, Hugo Chapdelaine
No abstract text is available yet for this article.
September 14, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28906290/safety-considerations-with-the-use-of-corticosteroids-and-biologic-therapies-in-mild-to-moderate-ulcerative-colitis
#10
Raymond K Cross
BACKGROUND: The risk of corticosteroid-associated adverse events can limit the use of systemic corticosteroids. Oral, topically acting, second-generation corticosteroids that deliver drug to the site of inflammation, and biologic therapies, are effective treatment alternatives. The aim of this review was to evaluate the safety and tolerability of topically acting corticosteroids and biologic therapies versus oral systemic corticosteroids for ulcerative colitis (UC). METHODS: The PubMed database was searched for clinical and observational trials, systematic reviews, and case reports/series published between January 1950 and September 30, 2016...
October 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28870657/use-of-biologic-therapy-by-pregnant-women-with-inflammatory-bowel-disease-does-not-affect-infant-response-to-vaccines
#11
Dawn B Beaulieu, Ashwin N Ananthakrishnan, Christopher Martin, Russell D Cohen, Sunanda V Kane, Uma Mahadevan
BACKGROUND & AIMS: In women with inflammatory bowel diseases (IBDs), exposure to immunomodulator or biologic therapy has not been associated with adverse events during pregnancy or outcomes of newborns. We investigated whether exposure of patients to these agents during pregnancy affects serologic responses to vaccines in newborns. METHODS: We collected data from the Pregnancy in IBD and Neonatal Outcomes registry, which records outcomes of pregnant women with diagnosis of IBD receiving care at multiple centers in the United States, from 2007 through 2016...
September 1, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28858074/efficacy-of-combination-vedolizumab-and-ustekinumab-for-refractory-crohn-s-disease
#12
Kayci Huff-Hardy, Mai Bedair, Rebecca Vazquez, Ezra Burstein
No abstract text is available yet for this article.
August 29, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28858072/surgical-outcomes-in-vedolizumab-treated-patients-with-ulcerative-colitis
#13
Amy L Lightner, Nicholas P McKenna, Sara Moncrief, John H Pemberton, Laura E Raffals, Kellie L Mathis
BACKGROUND: Surgical outcomes and pouch outcomes in the setting of vedolizumab remains poorly understood. We sought to determine the rate of 30-day postoperative surgical infectious complications and pouch-specific complications among patients with ulcerative colitis (UC) who received vedolizumab within 12 weeks of surgery. METHODS: A retrospective chart review between 5/1/2014 and 12/31/2016 of all adult patients with UC who underwent an abdominal operation was performed...
August 29, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28839909/vedolizumab-early-experience-and-medium-term-outcomes-from-two-uk-tertiary-ibd-centres
#14
Mark A Samaan, Polychronis Pavlidis, Emma Johnston, Ben Warner, Jonathan Digby-Bell, Ioannis Koumoutsos, Steven Fong, Rimma Goldberg, Kamal Patel, Shraddha Gulati, Lucy Medcalf, Marlene Sastrillo, Cordella Brown-Clarke, Johanna Bidewell-Sullivan, Katrina Forsyth, Emma Lee, Anna Stanton, Julie Duncan, Guy Chung-Faye, Patrick Dubois, Nick Powell, Simon Anderson, Jeremy Sanderson, Bu'Hussain Hayee, Peter M Irving
OBJECTIVE: To gain an understanding of the efficacy of vedolizumab in a 'real-world' setting. DESIGN: Retrospective cohort study using prospectively maintained clinical records. SETTING: Two UK tertiary inflammatory bowel disease (IBD) centres. PATIENTS: Patients with IBD commenced on vedolizumab at Guy's & St Thomas' and King's College Hospitals during November 2014-November 2015. INTERVENTION: Vedolizumab, a monoclonal antibody to α-4 β-7 integrins that selectively inhibit leucocyte migration into the gut...
July 2017: Frontline Gastroenterology
https://www.readbyqxmd.com/read/28839868/evolving-strategies-to-reduce-colectomy-rates-in-primary-sclerosing-cholangitis-inflammatory-bowel-disease-clinical-remission-of-corticosteroid-refractory-colitis-post-liver-transplant-with-vedolizumab
#15
Saqib Mumtaz, Jason Goh, Gideon M Hirschfield, James Ferguson, Sheldon C Cooper
Primary sclerosing cholangitis (PSC) is associated with inflammatory bowel disease (IBD) in approximately 70% of patients, with ulcerative colitis (UC) being the most common subtype of IBD identified. There is a paucity of data on the optimum management strategy for IBD flares in the post-liver transplant patient, particularly when refractory to conventional treatments. Vedolizumab is a novel gut-specific monoclonal antibody, which has recently been approved for use by National Institute for Health and Care Excellence for moderate-to-severe UC...
October 2016: Frontline Gastroenterology
https://www.readbyqxmd.com/read/28838418/ustekinumab-and-anti-interleukin-23-agents-in-crohn-s-disease
#16
REVIEW
Parakkal Deepak, William J Sandborn
This article reviews the available data regarding the efficacy of ustekinumab across published randomized clinical trials and open-label experience from tertiary medical centers, safety data, including in pregnancy, and its use in patients who have failed tumor necrosis factor (TNF) antagonists as well as patients who have not failed TNF antagonists. We have proposed an algorithm for positioning the use of ustekinumab among other agents (TNF antagonists, vedolizumab) in moderate-severe Crohn's disease. The article also enumerates drugs that are specific interleukin-23 blockers, including brazikumab (MEDI2070), risankizumab, LY3074828, tildrakizumab, and guselkumab, and the current status of their clinical trials...
September 2017: Gastroenterology Clinics of North America
https://www.readbyqxmd.com/read/28838417/use-of-anti-tumor-necrosis-factors-and-anti-integrins-in-the-treatment-of-crohn-s-disease
#17
REVIEW
Raina Shivashankar, Darrell S Pardi
In patients with Crohn's disease (CD), anti-tumor necrosis factor (TNF) therapy is efficacious for the induction and maintenance of clinical remission, mucosal healing, reducing rates of surgery and hospitalizations, and improving health-related quality of life. The decision between anti-TNFs and anti-integrins as first-line treatment in CD depends on disease severity, safety concerns, and prescription coverage. Given the existing data on long-term outcomes and safety, anti-TNFs are often preferred to anti-integrins...
September 2017: Gastroenterology Clinics of North America
https://www.readbyqxmd.com/read/28832222/natalizumab-in-the-treatment-of-crohn-s-disease-patients
#18
Cristiano Pagnini, Kristen O Arseneau, Fabio Cominelli
Amongst the available therapies for moderate to severe Crohn's disease (CD) patients who are refractory to conventional therapy, anti-TNF blockers are the most effective biological treatment option. However, many patients experience a primary or secondary non-response to anti-TNF therapy, creating the need for alternative biological drugs that target different mechanisms of action and inflammatory pathways. Natalizumab, the first non-anti-TNF biological drug to be approved for treatment of CD patients, is a recombinant humanized antibody that targets the α4-subunit of both α4β1 and α4β7 integrins, thus preventing activated leukocyte homing to the intestinal mucosa...
August 23, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28829369/systemic-chemokine-levels-with-gut-specific-vedolizumab-in-patients-with-inflammatory-bowel-disease-a-pilot-study
#19
Stephanie Zwicker, Ronaldo Lira-Junior, Charlotte Höög, Sven Almer, Elisabeth A Boström
Vedolizumab, a gut-specific biological treatment for inflammatory bowel disease (IBD), is an antibody that binds to the α₄β₇ integrin and blocks T-cell migration into intestinal mucosa. We aimed to investigate chemokine levels in serum of IBD-patients treated with vedolizumab. In this pilot study, we included 11 IBD patients (8 Crohn's disease, 3 ulcerative colitis) previously non-respondent to anti-tumor necrosis factor (TNF)-agents. Patients received vedolizumab at week 0, 2 and 6 and were evaluated for clinical efficacy at week 10...
August 22, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28815034/compliance-with-the-faecal-calprotectin-test-in-patients-with-inflammatory-bowel-disease
#20
Chloé Maréchal, Isabelle Aimone-Gastin, Cédric Baumann, Bastien Dirrenberger, Jean-Louis Guéant, Laurent Peyrin-Biroulet
BACKGROUND: We investigated, for the first time, levels of compliance with faecal calprotectin test in inflammatory bowel disease patients. METHODS: All consecutive adult inflammatory bowel disease patients having been prescribed an faecal calprotectin test between December 2014-July 2015 were included. At their next visit to the hospital, patients had to return a stool sample for the faecal calprotectin test and answer a simple questionnaire: 'Have you brought a stool sample? If not, why not? If so, did you encounter any difficulties when collecting the sample? Were you aware of faecal calprotectin before being asked to take the test?'...
August 2017: United European Gastroenterology Journal
keyword
keyword
1883
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"